ClinVar Miner

Submissions for variant NM_000038.6(APC):c.1213C>T (p.Arg405Ter)

gnomAD frequency: 0.00001  dbSNP: rs587779780
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 16
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000202096 SCV000148975 pathogenic not provided 2023-03-06 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 20223039, 30257133, 29901124, 1338764, 20685668, 15986289, 26681312, 33087929, 35189564)
Ambry Genetics RCV000115066 SCV000186398 pathogenic Hereditary cancer-predisposing syndrome 2021-12-10 criteria provided, single submitter clinical testing The p.R405* pathogenic mutation (also known as c.1213C>T), located in coding exon 9 of the APC gene, results from a C to T substitution at nucleotide position 1213. This changes the amino acid from an arginine to a stop codon within coding exon 9. This mutation has been reported in multiple individuals diagnosed with typical or attenuated familial adenomatous polyposis (FAP) (Nagase H et al. Hum Mutat, 1992;1:467-73; Friedl W et al. Hered Cancer Clin Pract, 2005 Sep;3:95-114; Yurgelun MB et al. J Clin Oncol, 2017 Apr;35:1086-1095; Pang M et al. Mol Med Rep, 2018 Aug;18:1423-1432). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV003534335 SCV000282691 pathogenic Familial adenomatous polyposis 1 2024-01-18 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg405*) in the APC gene. RNA analysis indicates that this premature translational stop signal induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with familial adenomatous polyposis (PMID: 1338764, 20223039, 20685668). ClinVar contains an entry for this variant (Variation ID: 127275). Studies have shown that this premature translational stop signal results in skipping of exon 10 and introduces a premature termination codon (Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic.
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000234357 SCV000803187 pathogenic Familial adenomatous polyposis 1 2018-06-26 criteria provided, single submitter research
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000202096 SCV000885014 pathogenic not provided 2022-02-08 criteria provided, single submitter clinical testing The APC c.1213C>T; p.Arg405Ter variant (rs587779780) has been reported in multiple individuals with familial adenomatous polyposis (Friedl 2005, Nagase 1992). It is listed as pathogenic in ClinVar (Variation ID: 127275), and not observed in the general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. The variant introduces a premature termination codon, and is predicted to result in a truncated protein or an absent transcript. Based on the above information, this variant is considered pathogenic. References: Friedl W et al. Familial adenomatous polyposis: experience from a study of 1164 unrelated german polyposis patients. Hered Cancer Clin Pract. 2005; 3(3):95-114. Nagase H et al. Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients. Hum Mutat. 1992; 1(6):467-73.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000202096 SCV000887502 pathogenic not provided 2017-11-16 criteria provided, single submitter clinical testing
Revvity Omics, Revvity Omics RCV000202096 SCV002017562 pathogenic not provided 2019-03-25 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV000234357 SCV004043982 pathogenic Familial adenomatous polyposis 1 2023-04-28 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.
New York Genome Center RCV000234357 SCV004176080 pathogenic Familial adenomatous polyposis 1 2023-04-11 criteria provided, single submitter clinical testing The c.1213C>T variant in APC has previously been reported in multiple individuals with typical or attenuated familial adenomatous polyposis [PMID: 1338764,20223039, 28135145, 35189564, 30257133, 29901124, 15986289, 26681312, 33087929], and it has been deposited in ClinVar [ClinVar ID: 127275] as Pathogenic by multiple submitters. The c.1213C>T variant is observed in 1 allele (0.00018% minor allele frequency with 0 homozygotes) in population databases (gnomAD v2.1.1 andv3.1.2, TOPMed Freeze 8) suggesting it is not a common benign variant in the populations represented in those databases. The c.1213C>T variant is located in exon 10 of this 16-exon gene, predicted to incorporate a premature termination codon (p.(Arg405Ter)), and is expected to result in loss-of-function via nonsense-mediated decay. Multiple loss-of-function variants that are downstream to the c.1213C>T variant have been reported in the literature and public variant repositories in individuals with familial adenomatous polyposis. Based on available evidence this heterozygous c.1213C>T p.(Arg405Ter) variant identified in APC is classified as Pathogenic.
Baylor Genetics RCV000234357 SCV004195188 pathogenic Familial adenomatous polyposis 1 2023-10-30 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003479005 SCV004223561 pathogenic Familial multiple polyposis syndrome 2023-11-09 criteria provided, single submitter clinical testing Variant summary: APC c.1213C>T (p.Arg405X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 250352 control chromosomes. c.1213C>T has been reported in the literature in individuals affected with Familial Adenomatous Polyposis (e.g. Lee_2022). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 35189564). Eight submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Color Diagnostics, LLC DBA Color Health RCV000115066 SCV004361854 pathogenic Hereditary cancer-predisposing syndrome 2023-08-07 criteria provided, single submitter clinical testing This variant changes 1 nucleotide in exon 10 of the APC gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with familial adenomatous polyposis and attenuated familial adenomatous polyposis (PMID: 1338764, 15952110, 15986289, 20223039, 20685668, 28135145, 29901124). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of APC function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Mayo Clinic Laboratories, Mayo Clinic RCV000202096 SCV000256910 pathogenic not provided no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV000202096 SCV000591065 pathogenic not provided no assertion criteria provided clinical testing The p.Arg405X variant has been previously reported in at least 4 of 2632 proband chromosomes in individuals with FAP ( Nagase 1992, Friedl 2005). In addition, this variant has been identified as a frequent mutation in somatic colorectal cancer (Harismendy 2011, Powell 1992). The p.Arg405X variant leads to a premature stop codon at position 405, which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the APC gene are an established mechanism of disease for FAP. In summary, based on the above information, this variant meets our criteria to be classified as pathogenic.
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000202096 SCV001956725 pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000202096 SCV001965783 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.